Navigation Links
DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
Date:12/19/2007

LA JOLLA, Calif., Dec 19 /PRNewswire/ -- DermTech, Inc., a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, announced that it has been issued Patent No. 7,297,480 by the United States Patent and Trademark Office. The patent, entitled: "Method for Detection of Melanoma", includes claims focused on non-invasive methods for detecting early-stage melanoma and for staging, and claims for monitoring melanoma in a subject.

The patent claims the use of DermTech's "tape stripping" technology for the purposes of detecting, staging and monitoring melanoma. The methods claimed in the patent focus on the use of DermTech's EGIR (Epidermal Genetic Information Retrieval, a skin sampling technique known as "tape stripping" in combination with a molecular diagnostic assay). Specifically, adhesive tape is placed over a lesion suspicious for melanoma and then removed to harvest the top layer of skin cells. The RNA is extracted and analyzed to determine and compare the level of a key melanoma marker, Interleukin-2 Receptor 1 (IL-2 R1), with the level in a normal skin control sample. A decrease in IL-2 R1 is indicative of early-stage melanoma. The patent also claims the use of evaluating additional biomarkers based upon differences in gene expression such that a change in these messenger RNAs is indicative of late-stage melanoma. The ability to detect, stage and monitor disease is critical for improved clinical outcomes.

"DermTech welcomes the issuance of this patent as it will allow us to move forward and more fully develop and position our core EGIR technology for the staging as well as the detection, of melanoma," said George Schwartz, CEO, DermTech. "This patent is an important addition to our intellectual property portfolio."

The incidence rate of malignant melanoma is increasing faster than any other cancer. Treatment involves surgical excision of the primary lesion, and vigilant monitoring to detect recurrence. The methods for detecting malignant melanoma described in DermTech's newly issued patent can serve as the basis for therapeutic decisions, saving many lives and reducing costs by avoiding unnecessary excisions and biopsies.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens derived from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information, visit http://www.dermtech.com

Contacts:

DermTech

George Schwartz

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
2. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
10. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):